obeldesivir (GS-5245) / Gilead  >>  Phase 3
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
obeldesivir (GS-5245) / Gilead
BIRCH, NCT05603143 / 2022-002741-18: Study of Obeldesivir in Participants With COVID-19 Who Have a High Risk of Developing Serious or Severe Illness

Terminated
3
468
Europe, Canada, Japan, RoW
Obeldesivir, GS-5245, Obeldesivir Placebo
Gilead Sciences
COVID-19
11/23
11/23
OAKTREE, NCT05715528: Study of Obeldesivir in Nonhospitalized Participants With COVID-19

Completed
3
2011
Japan, US
Obeldesivir, GS-5245, Obeldesivir Placebo
Gilead Sciences
COVID-19
11/23
01/24
NCT05996744: Study of Obeldesivir in Children and Adolescents With COVID-19

Terminated
2/3
3
US
Obeldesivir, GS-5245
Gilead Sciences
COVID-19
02/24
02/24

Download Options